Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
As a member of the Industry Expert Forum, CSL Behring will support a COPD Foundation initiative to create a framework that me…
The new facility in Broadmeadows (Victoria), the largest of its kind in the Southern Hemisphere, is part of CSL’s multibillio…
When it’s dark and cold, it’s easy to feel SAD, also known as seasonal affective disorder. Here are three views on how to mak…
A conversation with Pierluigi Tricoci, CSL Behring’s Global Product Leader, Cardiovascular and Metabolic (CVM) Therapeutic Ar…
NORD and the Rare Disease Diversity Coalition form a partnership to shed light on access for underrepresented patients.
For people who live with rare and chronic illness, the holiday whirlwind sometimes calls for “plan B.”
Arthur is stepping forward for those also living with chronic inflammatory demyelinating polyneuropathy (CIDP).
CSL’s Ellyn Getz, Director of R&D Patient Partnerships, visits the Advarra podcast to talk about how clinical research studie…
The bleeding disorder hemophilia B goes by an alternate name all because of a 5-year-old boy.
Americas
Asia Pacific
Middle East
Europe